Free Trial

Verici Dx (VRCI) Competitors

Verici Dx logo
GBX 4 -0.25 (-5.88%)
As of 04:20 AM Eastern

VRCI vs. AGL, YGEN, ABDX, PRM, GDR, GENI, IDHC, LLAI, DMTR, and LLA

Should you be buying Verici Dx stock or one of its competitors? The main competitors of Verici Dx include ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), GENinCode (GENI), Integrated Diagnostics (IDHC), LungLife AI (LLAI), Deepmatter Group (DMTR), and LLA.L,0P0001T9GN,0 (LLA). These companies are all part of the "diagnostics & research" industry.

Verici Dx vs.

ANGLE (LON:AGL) and Verici Dx (LON:VRCI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability.

Verici Dx has higher revenue and earnings than ANGLE. Verici Dx is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.02M21.22-£18.03M-£0.07-189.86
Verici Dx£4.33M2.24-£4.81M-£0.02-200.00

18.8% of ANGLE shares are held by institutional investors. Comparatively, 51.9% of Verici Dx shares are held by institutional investors. 16.2% of ANGLE shares are held by company insiders. Comparatively, 17.1% of Verici Dx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ANGLE received 182 more outperform votes than Verici Dx when rated by MarketBeat users.

CompanyUnderperformOutperform
ANGLEOutperform Votes
182
62.33%
Underperform Votes
110
37.67%
Verici DxN/AN/A

ANGLE has a net margin of 0.00% compared to Verici Dx's net margin of -110.99%. Verici Dx's return on equity of -58.12% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLEN/A -63.75% -29.89%
Verici Dx -110.99%-58.12%-26.14%

ANGLE currently has a consensus target price of GBX 70, suggesting a potential upside of 426.71%. Given ANGLE's stronger consensus rating and higher probable upside, research analysts clearly believe ANGLE is more favorable than Verici Dx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANGLE
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verici Dx
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

ANGLE has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Verici Dx has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

In the previous week, ANGLE's average media sentiment score of 0.00 equaled Verici Dx'saverage media sentiment score.

Company Overall Sentiment
ANGLE Neutral
Verici Dx Neutral

Summary

Verici Dx beats ANGLE on 8 of the 15 factors compared between the two stocks.

Get Verici Dx News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRCI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRCI vs. The Competition

MetricVerici DxDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£9.70M£30.36M£5.38B£2.05B
Dividend YieldN/A5.44%5.37%5.17%
P/E Ratio-200.002.0986.941,931.84
Price / Sales2.242,349.791,267.38397,059.81
Price / Cash1.3111.4236.6029.27
Price / Book1.003.114.973.09
Net Income-£4.81M£53.40M£117.89M£183.87M
7 Day Performance-5.88%7.32%1.72%1.55%
1 Month Performance59.17%7.88%3.67%3.95%
1 Year Performance-57.45%-9.28%26.11%42.77%

Verici Dx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRCI
Verici Dx
N/AGBX 4
-5.9%
N/A-55.0%£9.70M£4.33M-200.0019
AGL
ANGLE
1.4127 of 5 stars
GBX 11.18
+0.5%
GBX 70
+526.1%
-35.9%£36.06M£2.02M-159.71650
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 7.78
-2.8%
N/A-2.9%£14.74M£6.13M-899.0084Gap Down
PRM
Proteome Sciences
N/AGBX 4.50
+4.4%
N/A-11.9%£13.28M£4.04M-450.00240Gap Up
GDR
genedrive
N/AGBX 2.07
-3.7%
N/A-69.7%£11.25M£49,000.00-51.7843Gap Down
GENI
GENinCode
N/AGBX 3.10
-6.1%
N/A-36.8%£5.49M£2.60M-62.002,300Gap Down
IDHC
Integrated Diagnostics
N/AGBX 0.44
-2.9%
N/A+24.8%£2.56M£4.75B14.676,692
LLAI
LungLife AI
N/AGBX 7.41
-1.2%
N/A-83.9%£2.27M£98,566.00-57.0015Gap Up
High Trading Volume
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap Down
LLA
LLA.L,0P0001T9GN,0
N/AN/AN/AN/A£0.00N/A-125.0015High Trading Volume

Related Companies and Tools


This page (LON:VRCI) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners